Recent Advances, Controversies, and Emerging Trends in MBC
Medical Community, Clinical Research, Obstacles to Better Outcomes, Clinical Trials Process, Novel Treatments, Diagnosis and Treatment Our MBClife Medical Community, Clinical Research, Obstacles to Better Outcomes, Clinical Trials Process, Novel Treatments, Diagnosis and Treatment Our MBClife

Recent Advances, Controversies, and Emerging Trends in MBC

Over the last 20 years, advances in HER2 targeting treatments, antibody-drug conjugates (ADCs), immune checkpoint inhibitors (ICIs), and cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6is) have prolonged survival and changed the breast cancer treatment landscape. Success leads to more questions about optimal drug sequencing, mechanisms of resistance, and how to overcome that resistance. Let’s ask Dr. Stephanie Graff to help us tackle these topics and more.

Read More
ASCO 2022: When the Dust Settles, Will ADCs Change MBC?
Novel Treatments, Clinical Research, Medical Community, Entities of Cancer, Diagnosis and Treatment, Difficult to Treat, Updates from Conferences Our MBClife Novel Treatments, Clinical Research, Medical Community, Entities of Cancer, Diagnosis and Treatment, Difficult to Treat, Updates from Conferences Our MBClife

ASCO 2022: When the Dust Settles, Will ADCs Change MBC?

While HER2-Low and DESTINY-Breast04 garnered most of the headlines from the ASCO 2022 in June, it was not the only reason for optimism. Our MBC Life takes a deeper dive with Dr. Stephanie Graff and Dr. Hope Rugo in this first episode of our two-part series.

Read More
Road to a Cure - ADC & SARM
Novel Treatments, Medical Community, Challenges and Barriers, Health Disparities, Diagnosis and Treatment, Entities of Cancer, MBC Imaging and Profiling, Immunotherapy, Difficult to Treat, Clinical Research, Long Term Adverse Effects Our MBClife Novel Treatments, Medical Community, Challenges and Barriers, Health Disparities, Diagnosis and Treatment, Entities of Cancer, MBC Imaging and Profiling, Immunotherapy, Difficult to Treat, Clinical Research, Long Term Adverse Effects Our MBClife

Road to a Cure - ADC & SARM

How famous is Dr Hope Rugo? She belongs to a tiny elite group of oncologists who have their own Wikipedia page. Dr. Dennis Slamon is quite possibly the only other member. Enough said. No surprise that we can’t wait to hear what she has to say about a new class of drugs, known as ADCs and specifically, the first ADC for mTNBC that already has a nickname – Sassy (sacituzumab govitecan). Do you know what a SARM is? It is a special class of drugs for those who are Androgen Receptor (AR) positive. Listen and find out.

Read More